Gene Therapy for Viral Infections

Gene Therapy for Viral Infections

By (author) 

Free delivery worldwide

Available. Dispatched from the UK in 1 business day
When will my order arrive?


Gene Therapy for Viral Infections provides a comprehensive review of the broader field of nucleic acid and its use in treating viral infections. The text bridges the gap between basic science and important clinical applications of the technology, providing a systematic, integrated review of the advances in nucleic acid-based antiviral drugs and the potential advantages of new technologies over current treatment options.

Coverage begins with the fundamentals, exploring varying topics, including harnessing RNAi to silence viral gene expression, antiviral gene editing, viral gene therapy vectors, and non-viral vectors.

Subsequent sections include detailed coverage of the developing use of gene therapy for the treatment of specific infections, the principles of rational design of antivirals, and the hurdles that currently face the further advancement of gene therapy technology.
show more

Product details

  • Hardback | 392 pages
  • 191 x 235 x 22.86mm | 1,040g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0124105181
  • 9780124105188

Table of contents

1. Essentials of Gene Therapy for Viral infections 2. Harnessing RNAi to silence Viral Gene Expression 3. Antiviral sequence-specific DNA binding proteins 4. Viral Gene Therapy Vectors 5. Nonviral vectors 6. Gene therapy for HBV infection 7. Gene therapy for HCV infection 8. Gene therapy for HIV infection 9. Gene therapy for respiratory and other viral infections 10. Gene therapy for hemorrhagic fever viruses 11. Gene transfer for vaccination against viral infection 12. Conclusion
show more

About Patrick Arbuthnot

Patrick Arbuthnot is currently a personal professor and director of the Antiviral Gene Therapy Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. After completing a medical degree and then a PhD, he carried out post-doctoral research on gene therapy for liver diseases at Necker Hospital in Paris. For more than ten years, his primary research focus has been on advancing gene silencing and gene editing technologies to develop improved treatment of chronic hepatitis B virus infection. In addition, he has worked on furthering methods of disabling genes of HIV-1, Rift Valley Fever virus and hepatitis C virus. Dr Arbuthnot has been an author of numerous publications and edited scientific books on topics related to antiviral gene therapy.
show more